Drug and disease signature integration identifies synergistic combinations in glioblastoma

Abstract excerpt

Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed SynergySeq to identify drug combinations for the treatment of GBM by integrating information from The Cancer Genome...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bioinformatics and Genomic Networks
• Share to Glioma Diagnosis and Treatment
• Share to Protein Degradation and Inhibitors